TY014

Anti-yellow fever virus human antibody

Networked: 1 relevant articles (1 outcomes, 1 trials/studies)

1.	Viremia 01/01/2020 - "At 48 hours after the infusion, none of the 5 participants who received the starting dose of TY014 of 2 mg per kilogram had detectable YF17D-204 viremia; these participants remained aviremic throughout the trial. " 01/01/2020 - "The primary efficacy outcome was the dose of TY014 at which 100% of the participants tested negative for viremia within 48 hours after infusion. " 01/01/2020 - "In a double-blind, phase 1b clinical trial, we assessed the efficacy of TY014, as compared with placebo, in abrogating viremia related to the administration of live yellow fever vaccine (YF17D-204; Stamaril). "
2.	Body Weight (Weight, Body) 01/01/2020 - "During phase 1a, TY014 dose escalation to a maximum of 20 mg per kilogram of body weight occurred in 22 participants. "

1.	Yellow Fever Vaccine (Vaccine, Yellow Fever)